CannabisNewsBreaks

WednesdayFeb 16, 2022 1:49 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial results that reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3 million, all cannabichromene (“CBC”). “As of January, it also began selling cannabicitran (‘CBT’) to the health and wellness market,” notes the report. “The now-completed BayMedica acquisition boosts its product portfolio for rare cannabinoids and rounds…

Continue Reading

TuesdayFeb 15, 2022 12:36 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing products as well as the launch of new products. Griffin brings a rich background to this position, having a proven track record as a veteran sales executive. He has served in several senior positions in Fortune 500 companies, including most recently as VP of sales…

Continue Reading

MondayFeb 14, 2022 2:28 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies

InMed Pharmaceuticals (NASDAQ: INM) understands the immense potential of rare cannabinoids and sees them as having applications as wide as cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), variants of cannabinoids that make up most of the content in cannabis plants. Studies suggest that rare cannabinoids could offer more potent medical benefits than CBD and without the psychoactive attribute of THC, representing a huge market. “However, the industry wide problem has always been to obtain the production scales necessary for cost-effective commercialization of such compounds, while also ensuring the purity and consistency that can be difficult at even low volumes. The answer is…

Continue Reading

MondayFeb 14, 2022 2:07 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Furthering Global Foothold as Leader in Plant-Based Wellness, Lifestyle Brands

Flora Growth Corp. (NASDAQ: FLGC) is expanding its cannabis-derived brand presence in Latin American countries. Its Mind Naturals skincare brand, built with premium CBD and other high-quality ingredients, will be distributing a portfolio of 12 products through its agreement with Walmart’s online marketplace and Coppel e-commerce outlets. Walmart and Coppel are leading retail chains in Mexico and Central America. A recent article quotes Flora Growth CEO Luis Merchan as saying, “This agreement represents our first foray into the Mexican market and furthers our global foothold as a leader in plant-based wellness and lifestyle brands… As the cannabis market continues its…

Continue Reading

FridayFeb 11, 2022 1:12 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Chris Bunka noted that Lexaria would continue to see significant milestones in utilizing its patented DehydraTECH drug delivery technology in 2022. “Calendar 2022 will continue to see significant milestones utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking… We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease and diabetes,” a recent article quotes Bunka as saying. Lexaria received independent review board approval, marking…

Continue Reading

ThursdayFeb 10, 2022 12:20 pm

CannabisNewsBreaks – RYAH Group Inc. (CSE: RYAH) Receives Notice of Allowance by USPTO for Smart Medical Inhaler System

RYAH Group (CSE: RYAH) today announced that the U.S. Patent and Trademark Office (the “USPTO”) has issued a Notice of Allowance for U.S. patent application number 15/924,172, filed in respect of the company's IoT-powered, Smart Medical Inhaler system by its wholly owned subsidiary, Potbotics Inc. The hybrid conduction and convection RYAH Smart Medical Inhaler was recently granted Medical Device Certification under ISO 13485:2016/MDSAP and EN ISO 13485:2016 standards for both its hardware and software. “Receiving this Notice of Allowance by the USPTO on our Smart Medical Inhaler is the result of dedication and great effort by all of our product…

Continue Reading

TuesdayFeb 08, 2022 2:59 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Reaches ‘Major Milestone,’ Closes on Acquisition

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, through its wholly owned subsidiary RWB Michigan LLC, has closed on the acquisition of PharmaCo Inc. The acquisition, which was originally announced in 2020, brings an extensive list of assets to RWBYF, including 21 medical and adult-use cannabis licenses, eight fully operating dispensaries with five dually licensed, two operational indoor cultivation facilities totaling more than 30,000 square feet, one municipally licensed 10-acre outdoor cultivation facility ready for the 2022 season, two ready-to-open dispensaries, and22 owned properties for potential additional cultivation and dispensary locations.…

Continue Reading

FridayFeb 04, 2022 11:25 am

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Vertically Integrating Across Multiple States

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) reported a 93% year-over-year revenue growth from $6.1 million in Q3 2020 to $11.8 million in Q3 2021. According to RWB chairman and CEO Brad Rogers, the company made excellent progress in laying additional building blocks in its core operating states of Florida, Michigan and California to become more vertically integrated “where it will be most profitable.” In Florida, the company’s operations include active cannabis cultivation sites, an operational processing facility and a dispensary. In Michigan, RWB expects to be vertically integrated upon closing a pending acquisition of an investee whose…

Continue Reading

WednesdayFeb 02, 2022 2:59 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Blazing Trail in Defining Value of Rare Cannabinoids in Pharmaceutical Space

InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering there are over 100 known cannabinoids, including rare ones that are quickly taking over and will soon dominate the market. The potency of rare cannabinoids has given them powerful health benefits, hence their demand within the cosmetics, food and beverage, health and wellness, and pharmaceutical sectors. “InMed’s most advanced compound, INM-755, has already proven helpful in treating epidermolysis bullosa, a…

Continue Reading

WednesdayFeb 02, 2022 2:20 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. The study was designed to evaluate LEXX’s proprietary DehydraTECH(TM) processing of the phosphodiesterase inhibitor ("PDE5 inhibitor") sildenafil for potential use in the management of erectile dysfunction. According to the company, the DehydraTECHsildenafil delivered 74% more drug at four minutes than the concentration-matched, generic control formulation with faster and higher overall delivery of sildenafil into the bloodstream evidenced over the course of the study. The most recognizable sildenafil product available currently is Viagra(R), but some users find it slow to act. Lexaria hopes…

Continue Reading